We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus
Read MoreHide Full Article
Two of the three widely followed indexes closed last week with marginally higher, while one closed in the red. The S&P 500 and the Dow Jones Industrial Average jumped 0.5% and 0.8%, respectively, while the tech-heavy Nasdaq Composite lost 0.2%. For the S&P 500, it was a second straight weekly advance, while the Dow snapped two weeks of losses.
The stock market continues to be in a turbulent mode, unable to make up its mind about the direction the economy is taking. While there was visible respite in investor sentiment after the release of the minutes from the Fed September meeting, which showed the central bank taking a dovish stance on policy tightening, higher-than-expected inflation numbers diluted the vibes somewhat. The bond yields also see-sawed through the week, with the 10-year treasury yield coming down from 16-year highs and the 2-year yield continuing to climb northward.
The conflict raging in the Gaza strip kept the investors on tenterhooks while sharply dropping consumer sentiments ensured the week ended on a whimpering note. Investors continue to closely monitor how the oil prices react to the Israel-Palestine tussle and whether the higher-than-expected inflation changes the Fed’s reading of the situation.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
MakeMyTrip and Corcept Therapeutics Surge Following Zacks Rank Upgrade
Shares of MakeMyTrip Limited (MMYT - Free Report) have gained 15.8% (versus the S&P 500’s 3.4% decrease) since it was upgraded to a Zacks Rank #1 (Strong Buy) on August 4.
Another stock, Corcept Therapeutics Incorporated (CORT - Free Report) , which was upgraded to a Zacks Rank #2 (Buy) on August 3, has returned 10.2% (versus the S&P 500’s 3.7% decrease) since then.
Zacks Rank, our short-term rating system, has earnings estimate revisions at its core. Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
A hypothetical portfolio of Zacks Rank #1 (Strong Buy) stocks returned +12.02% this year (through September 4th) vs. +18.2% for the S&P 500 index and +7.6% for the equal-weight S&P 500 index. The portfolio of Zacks Rank #1 stocks is an equal-weight portfolio, while the S&P 500 index is a market-cap-weighted index that has been notably distorted by the strong recent performance of mega-cap stocks.
We are not trying to cherry-pick here. But since this Zacks Model portfolio, consisting of Zacks Rank #1 stocks, is an equal-weight portfolio, the equal-weight S&P 500 index is the appropriate benchmark for comparison. Looked at this way, this portfolio has outperformed the index this year.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 13 percentage points since 1988 (Through September 4th, 2023, the Zacks # 1 Rank stocks has generated an annualized return of +24.17% since 1988 vs. +10.82% for the S&P 500 index).You can see the complete list of today’s Zacks Rank #1 stocks here >>>
Zacks Recommendation Upgrades SP Plus and Parsons Higher
Shares of SP Plus Corporation (SP - Free Report) and Parsons Corporation (PSN - Free Report) have advanced 33.1% (versus the S&P 500’s 3.7% fall) and 6.7% (versus the S&P 500’s 3.4% fall) since their Zacks Recommendation was upgraded to Outperform on August 3 and August 4, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Axon, Cheniere Energy Shoot Up
Shares of Axon Enterprise, Inc. (AXON - Free Report) , which belongs to the Zacks Focus List, have gained 19.7% over the past 12 weeks. The stock was added to the Focus List on June 3, 2020. Another Focus-List holding, Cheniere Energy, Inc. (LNG - Free Report) , which was added to the portfolio on September 6, 2022, has returned 11.7% over the past 12 weeks. The S&P 500 has declined 3.9% over this period.
The 50-stock Zacks Focus List model portfolio returned +22.3% in 2023 (through July 31st) vs. +20.6% for the S&P 500 index and +10.5% for the equal-weight S&P 500 index. In 2022, the portfolio produced -15.2% vs. the S&P 500 index’s -17.96%.
Since 2004, the Focus List portfolio has produced an annualized return of +11.27% through July 31st, 2023. This compares to a +9.65% annualized return for the S&P 500 index in the same time period.
On a rolling one-, three- and five-year bases, the Zacks Focus List returned +21.76%, +16.33%, and +12.54% vs. +12.99%, +13.71% and +12.19% for the S&P 500 index, respectively.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Novo Nordisk and Amgen Make Significant Gains
Novo Nordisk A/S (NVO - Free Report) , a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 23.3% over the past 12 weeks. Amgen Inc. (AMGN - Free Report) has followed Novo Nordisk with 21% returns.
ECAP, which consists of 30 concentrated, ultra-defensive, long-term Buy and Hold stocks, has returned +6.67% in 2023 (through June 30) versus +16.90% for the S&P 500 Index. The portfolio returned -4.7% in 2022 versus the S&P 500 Index’s -17.96%.
With little to no turnover and annual rebalance periodicity, the ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Automatic Data Processing and Fastenal Outperform Peers
Automatic Data Processing, Inc. (ADP - Free Report) , which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 4.1% over the past 12 weeks. Another ECDP stock, Fastenal Company (FAST - Free Report) , has climbed 3.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low Beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
ECDP has returned +0.18% in 2023 (through June 30) versus +16.90% for the S&P 500 Index. The portfolio returned -2.3% in 2022 versus -17.96% for the S&P 500 Index and -8.34% for the ProShares S&P 500 Dividend Aristocrats ETF (NOBL - Free Report) .
Zacks Top 10 Stocks — Celsius Delivers Solid Returns
Celsius Holdings, Inc. (CELH - Free Report) , from the Zacks Top 10 Stocks for 2023, has gained 57.3% year to date, which compares to a 14.1% gain for the S&P 500 Index.
The portfolio returned +16.16% through the end of July 2023 vs. +20.64% for the S&P 500 index and +10.73% for the equal-weighted version of the index. The portfolio returned -15.8% in 2022 vs. -18.1% for the S&P 500 index. Since 2012, the Top 10 portfolio has generated an annualized return of +22.78% vs. +13.65% for the S&P 500 index.
Since the start of 2012 through July 31st, 2023, the Zacks Top 10 Stocks has produced a cumulative return of +977.47% vs. +340.35% cumulative return for the S&P 500 index.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus
Two of the three widely followed indexes closed last week with marginally higher, while one closed in the red. The S&P 500 and the Dow Jones Industrial Average jumped 0.5% and 0.8%, respectively, while the tech-heavy Nasdaq Composite lost 0.2%. For the S&P 500, it was a second straight weekly advance, while the Dow snapped two weeks of losses.
The stock market continues to be in a turbulent mode, unable to make up its mind about the direction the economy is taking. While there was visible respite in investor sentiment after the release of the minutes from the Fed September meeting, which showed the central bank taking a dovish stance on policy tightening, higher-than-expected inflation numbers diluted the vibes somewhat. The bond yields also see-sawed through the week, with the 10-year treasury yield coming down from 16-year highs and the 2-year yield continuing to climb northward.
The conflict raging in the Gaza strip kept the investors on tenterhooks while sharply dropping consumer sentiments ensured the week ended on a whimpering note. Investors continue to closely monitor how the oil prices react to the Israel-Palestine tussle and whether the higher-than-expected inflation changes the Fed’s reading of the situation.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
MakeMyTrip and Corcept Therapeutics Surge Following Zacks Rank Upgrade
Shares of MakeMyTrip Limited (MMYT - Free Report) have gained 15.8% (versus the S&P 500’s 3.4% decrease) since it was upgraded to a Zacks Rank #1 (Strong Buy) on August 4.
Another stock, Corcept Therapeutics Incorporated (CORT - Free Report) , which was upgraded to a Zacks Rank #2 (Buy) on August 3, has returned 10.2% (versus the S&P 500’s 3.7% decrease) since then.
Zacks Rank, our short-term rating system, has earnings estimate revisions at its core. Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
A hypothetical portfolio of Zacks Rank #1 (Strong Buy) stocks returned +12.02% this year (through September 4th) vs. +18.2% for the S&P 500 index and +7.6% for the equal-weight S&P 500 index. The portfolio of Zacks Rank #1 stocks is an equal-weight portfolio, while the S&P 500 index is a market-cap-weighted index that has been notably distorted by the strong recent performance of mega-cap stocks.
We are not trying to cherry-pick here. But since this Zacks Model portfolio, consisting of Zacks Rank #1 stocks, is an equal-weight portfolio, the equal-weight S&P 500 index is the appropriate benchmark for comparison. Looked at this way, this portfolio has outperformed the index this year.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 13 percentage points since 1988 (Through September 4th, 2023, the Zacks # 1 Rank stocks has generated an annualized return of +24.17% since 1988 vs. +10.82% for the S&P 500 index).You can see the complete list of today’s Zacks Rank #1 stocks here >>>
Check MakeMyTrip’s historical EPS and Sales here>>>
Check Corcept’s historical EPS and Sales here>>>
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades SP Plus and Parsons Higher
Shares of SP Plus Corporation (SP - Free Report) and Parsons Corporation (PSN - Free Report) have advanced 33.1% (versus the S&P 500’s 3.7% fall) and 6.7% (versus the S&P 500’s 3.4% fall) since their Zacks Recommendation was upgraded to Outperform on August 3 and August 4, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Axon, Cheniere Energy Shoot Up
Shares of Axon Enterprise, Inc. (AXON - Free Report) , which belongs to the Zacks Focus List, have gained 19.7% over the past 12 weeks. The stock was added to the Focus List on June 3, 2020. Another Focus-List holding, Cheniere Energy, Inc. (LNG - Free Report) , which was added to the portfolio on September 6, 2022, has returned 11.7% over the past 12 weeks. The S&P 500 has declined 3.9% over this period.
The 50-stock Zacks Focus List model portfolio returned +22.3% in 2023 (through July 31st) vs. +20.6% for the S&P 500 index and +10.5% for the equal-weight S&P 500 index. In 2022, the portfolio produced -15.2% vs. the S&P 500 index’s -17.96%.
Since 2004, the Focus List portfolio has produced an annualized return of +11.27% through July 31st, 2023. This compares to a +9.65% annualized return for the S&P 500 index in the same time period.
On a rolling one-, three- and five-year bases, the Zacks Focus List returned +21.76%, +16.33%, and +12.54% vs. +12.99%, +13.71% and +12.19% for the S&P 500 index, respectively.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Novo Nordisk and Amgen Make Significant Gains
Novo Nordisk A/S (NVO - Free Report) , a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 23.3% over the past 12 weeks. Amgen Inc. (AMGN - Free Report) has followed Novo Nordisk with 21% returns.
ECAP, which consists of 30 concentrated, ultra-defensive, long-term Buy and Hold stocks, has returned +6.67% in 2023 (through June 30) versus +16.90% for the S&P 500 Index. The portfolio returned -4.7% in 2022 versus the S&P 500 Index’s -17.96%.
With little to no turnover and annual rebalance periodicity, the ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Automatic Data Processing and Fastenal Outperform Peers
Automatic Data Processing, Inc. (ADP - Free Report) , which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 4.1% over the past 12 weeks. Another ECDP stock, Fastenal Company (FAST - Free Report) , has climbed 3.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
Check Automatic Data Processing’s dividend history here>>>
Check Fastenal’s dividend history here>>>
With an extremely low Beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
ECDP has returned +0.18% in 2023 (through June 30) versus +16.90% for the S&P 500 Index. The portfolio returned -2.3% in 2022 versus -17.96% for the S&P 500 Index and -8.34% for the ProShares S&P 500 Dividend Aristocrats ETF (NOBL - Free Report) .
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stocks — Celsius Delivers Solid Returns
Celsius Holdings, Inc. (CELH - Free Report) , from the Zacks Top 10 Stocks for 2023, has gained 57.3% year to date, which compares to a 14.1% gain for the S&P 500 Index.
The portfolio returned +16.16% through the end of July 2023 vs. +20.64% for the S&P 500 index and +10.73% for the equal-weighted version of the index. The portfolio returned -15.8% in 2022 vs. -18.1% for the S&P 500 index. Since 2012, the Top 10 portfolio has generated an annualized return of +22.78% vs. +13.65% for the S&P 500 index.
Since the start of 2012 through July 31st, 2023, the Zacks Top 10 Stocks has produced a cumulative return of +977.47% vs. +340.35% cumulative return for the S&P 500 index.